Perspectives on the mGluR2/3 agonists as a therapeutic target for schizophrenia: Still promising or a dead end?

Progress in Neuro-psychopharmacology & Biological Psychiatry
Meng-Lin LiWen-Jun Gao

Abstract

Group II metabotropic glutamate receptor (mGluR2/3) agonists once showed promise as non-dopaminergic antipsychotic drugs because of their efficacy in alleviating symptoms of schizophrenia (SZ) in both animal models and human patients. However, the recent failure of Phase III clinical trials dealt a huge blow to the scientific community and the aftershock of the setback in mGluR2/3 research can be felt everywhere from grant support and laboratory studies to paper publication. An immediate question raised is whether mGluR2/3 is still a promising therapeutic target for schizophrenia. Answering this question is not easy, but apparently a new strategy is needed. This article provides a focused review of literature on the study of mGluR2/3 agonists, especially on mGluR2/3 agonists' mechanism of action and efficacy in both normal conditions and animal models of SZ, as well as clinical studies in human patients with the disease. We argue that the cellular and molecular actions of mGluR2/3 agonists, the distinct roles between mGluR2 and mGluR3, as well as their effects on different stages of the disease and different subpopulations of patients, remain incompletely studied. Until the mechanisms associated with mGluR2/3 are clearly elucid...Continue Reading

References

Dec 1, 1995·Archives of General Psychiatry·J W Olney, N B Farber
Jan 1, 1997·Annual Review of Pharmacology and Toxicology·P J Conn, J P Pin
Feb 12, 1999·Brain Research. Brain Research Reviews·R Anwyl
Oct 26, 1999·Neuropharmacology·D D SchoeppJ A Monn
Jan 11, 2000·Journal of Psychiatric Research·J W OlneyN B Farber
Aug 29, 2001·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·V BrunoF Nicoletti
Jul 16, 2002·Pharmacology, Biochemistry, and Behavior·Aleksandra KłodzinskaAndrzej Pilc
Jun 26, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Daniel S LorrainLinda J Bristow
Aug 18, 2004·Proceedings of the National Academy of Sciences of the United States of America·Michael F EganDaniel R Weinberger
Feb 3, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Elena H ChartoffRichard D Palmiter
May 25, 2006·Current Topics in Medicinal Chemistry·Craig W LindsleyGene G Kinney
Aug 3, 2007·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Corrado CortiValeria Bruno
Sep 11, 2007·Nature Medicine·Daniel R Weinberger
Nov 30, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·William T Carpenter, James I Koenig
Jul 11, 2008·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Rainald MössnerWolfgang Maier
Dec 9, 2008·Trends in Pharmacological Sciences·P Jeffrey ConnCarrie K Jones
Mar 28, 2009·Schizophrenia Bulletin·Oliver D Howes, Shitij Kapur
Jan 9, 2010·Annual Review of Pharmacology and Toxicology·Colleen M Niswender, P Jeffrey Conn
Apr 8, 2010·European Journal of Pharmacology·Gerard J Marek

❮ Previous
Next ❯

Citations

Dec 22, 2015·Neuron·UNKNOWN BrainSeq: A Human Brain Genomics Consortium. Electronic address: drweinberger@libd.org, UNKNOWN BrainSeq: A Human Brain Genomics Consortium
Jul 5, 2016·Current Treatment Options in Psychiatry·Gary RemingtonMargaret Hahn
May 24, 2016·Psychopharmacology·Katherine BeckOliver D Howes
Feb 1, 2017·The Journal of Pharmacology and Experimental Therapeutics·Christian C FelderJames A Monn
Mar 26, 2019·Journal of Alzheimer's Disease : JAD·Kevin N HascupErin R Hascup
May 19, 2017·Frontiers in Molecular Neuroscience·Michelle D GjørlundSylwia Owczarek
Aug 17, 2019·Frontiers in Molecular Neuroscience·Gloria Lee, Yi Zhou
Jun 28, 2018·Acta Pharmacologica Sinica·Yong-Jian HuJian-Feng Liu
Jan 22, 2019·Frontiers in Molecular Neuroscience·Vanessa Pereira, Cyril Goudet
Nov 26, 2020·International Journal of Molecular Sciences·Paulina Cieślik, Joanna M Wierońska
Feb 2, 2021·The FEBS Journal·Praachi TiwariVidita A Vaidya
May 1, 2021·Journal of Clinical Medicine·Waldemar Kryszkowski, Tomasz Boczek
Jun 17, 2020·Current Drug Targets·Hemen S Ved, Gaurav M Doshi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Astrocytes

Astrocytes are glial cells that support the blood-brain barrier, facilitate neurotransmission, provide nutrients to neurons, and help repair damaged nervous tissues. Here is the latest research.

Anti-N-Methyl-D-Aspartate Receptor Encephalitis

Anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis is a form of of brain inflammation due to antibodies against NMDA receptors. Discover the latest research on anti-NMDA receptor encephalitis here.

Bipolar Disorder

Bipolar disorder is characterized by manic and/or depressive episodes and associated with uncommon shifts in mood, activity levels, and energy. Discover the latest research this illness here.

Astrocytes in Repair & Regeneration

Astrocytes are glial cells found within the CNS and are able to regenerate new neurons. They become activated during CNS injury and disease. The activation leads to the transcription of new genes and the repair and regeneration of neurons. Discover the latest research on astrocytes in repair and regeneration here.

Astrocytes & Neurodegeneration

Astrocytes are important for the health and function of the central nervous system. When these cells stop functioning properly, either through gain of function or loss of homeostatic controls, neurodegenerative diseases can occur. Here is the latest research on astrocytes and neurodegeneration.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Addison Disease

Addison's disease, also known as primary adrenal insufficiency and hypocortisolism, is a long-term endocrine disorder in which the adrenal glands do not produce enough steroid hormones. Discover the latest research on Addison's disease here.

Attention Disorders

Attention is involved in all cognitive activities, and attention disorders are reported in patients with various neurological diseases. Here are the latest discoveries pertaining to attention disorders.